2. Signaling Pathways
  3. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
  4. EGFR

EGFR

Epidermal growth factor receptor; ErbB-1; HER1

EGFR

Related Products

PDF 3.8 MB

The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All EGFR family members are characterized by a modular structure consisting of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular part harbouring the highly conserved tyrosine kinase domain. The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ten growth factors and their ErbB specificities are: EGF, amphiregulin (AR), and TGF bind ErbB-1; betacellulin, and epiregulin bind both ErbB-1 and ErbB-4; the neuregulins (also called heregulins and Neu differentiation factors) NRG-1 and NRG-2 bind ErbB-3 and ErbB-4; and NRG-3 and NRG-4 bind ErbB-4. No known ligand binds ErbB-2. The three best characterized signaling pathways induced through ErbBs are Ras-mitogen-activated protein kinase (Ras-MAPK), phosphatidylinositol 3 kinase-protein kinase B (PI3K-PKB/Akt), and phospholipase C-protein kinase C (PLC-PKC) pathways.

EGFR Isoform Specific Products:

EGFR Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99618
    Fidasimtamab
    		Inhibitor
    Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity.
    Fidasimtamab
  • HY-13272S2
    Dacomitinib-d10 dihydrochloride
    		Inhibitor
    Dacomitinib-d10 dihydrochloride is the deuterium labeled Dacomitinib dihydrochloride. Dacomitinib (PF-00299804) dihydrochloride is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively.
    Dacomitinib-d<sub>10</sub> dihydrochloride
  • HY-164387
    Sutetinib
    		Inhibitor 99.27%
    Sutetinib is an orally active inhibitor for tyrosine kinase, that is associated with tumor growth and angiogenesis, such as VEGFR (Ki= 0.009 µM for VEGFR-1/2/3), PDGFR (Ki= 0.008 µM for PDGFR-α/β) and proto-oncogene cKIT. Sutetinib inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts, and exhibits board-spectrum antitumor efficacy in vitro and in vivo.
    Sutetinib
  • HY-10261R
    Afatinib (Standard)
    		Inhibitor
    Afatinib (Standard) is the analytical standard of Afatinib. This product is intended for research and analytical applications. Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.
    Afatinib (Standard)
  • HY-14347
    EBE-A22
    		Control 99.76%
    EBE-A22 is a derivative of PD153035, which can inhibit the phosphorylation of ErbB-1, but EBE-A22 does not have this activity.
    EBE-A22
  • HY-147219
    SIAIS164018
    		Inhibitor
    SIAIS164018 is a PROTAC-based ALK and EGFR degrader, with IC50 value of 2.5 nM and 6.6 nM for ALK and ALK G1202R, respectively. SIAIS164018 strongly inhibits cancer cells migration and invasion, causes G1 cell cycle arrest and induces apoptosis. SIAIS164018 exhibits better property than Brigatinib (HY-12857).
    SIAIS164018
  • HY-153111
    EGFR/HER2-IN-9
    		Inhibitor 98.73%
    EGFR/HER2-IN-9 (Compound 1) is an EGFR and HER2 inhibitor with IC50s of 3.2, 8.3 and 14 nM against EGFR, EGFR T790M and HER2, respectively.
    EGFR/HER2-IN-9
  • HY-111452
    EGFR-IN-85
    		Inhibitor
    EGFR-IN-85 (Compound 1) is an EGFR inhibitor. EGFR-IN-85 has IC50 value of 0.19 μM for EGFRvⅢ phosphorylation. EGFR-IN-85 can suppress EGFR signaling within tumors. EGFR-IN-85 can be used for Glioblastoma (GBM) research.
    EGFR-IN-85
  • HY-P2673
    Lys-Arg-Thr-Leu-Arg-Arg
    Lys-Arg-Thr-Leu-Arg-Arg (KRTLRR) is a hexapeptide. Lys-Arg-Thr-Leu-Arg-Arg is a substrate of protein kinase C from EGF receptor. Lys-Arg-Thr-Leu-Arg-Arg can be used to determine the activity of protein kinase C.
    Lys-Arg-Thr-Leu-Arg-Arg
  • HY-157413
    YS-67
    		Inhibitor 99.41%
    YS-67 is a potent inhibitor of EGFR with an IC 50 of 5.2 nM. YS-67 significantly inhibits p-EGFR and p-AKT. YS-67 inhibits the proliferation of A549, PC-9, and A431cells with IC 50s of 4.1, 0.5, and 2.1 μM, respectively.
    YS-67
  • HY-19617B
    EGFR-IN-1 TFA
    		Inhibitor 99.38%
    EGFR-IN-1 TFA is an orally active and irreversible L858R/T790M mutant selective EGFR inhibitor. EGFR-IN-1 TFA potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR. EGFR-IN-1 TFA displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity.
    EGFR-IN-1 TFA
  • HY-172429
    Enozertinib
    		Inhibitor
    Enozertinib is the inhibitor for EGFR that exhibits antineoplastic activity.
    Enozertinib
  • HY-P3744
    pp60v-src Autophosphorylation site
    		99.93%
    pp60v-src Autophosphorylation site is a synthetic peptide. pp60v-src Autophosphorylation site can be used for various biochemical studies.
    pp60v-src Autophosphorylation site
  • HY-P99854A
    Disitamab (powder)
    		Inhibitor 98.44%
    Disitamab (RC48-0) (powder) is a humanized monoclonal antibody targeting HER2. Disitamab (powder) can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985).
    Disitamab (powder)
  • HY-U00002
    ZD-4190
    		Inhibitor 98.08%
    ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer.
    ZD-4190
  • HY-P2673A
    Lys-Arg-Thr-Leu-Arg-Arg acetate
    Lys-Arg-Thr-Leu-Arg-Arg (KRTLRR) acetate is a hexapeptide. Lys-Arg-Thr-Leu-Arg-Arg acetate is a substrate of EGF receptor protein kinase C and can be used to measure protein kinase C activity.
    Lys-Arg-Thr-Leu-Arg-Arg acetate
  • HY-P99969
    Inetetamab
    		Inhibitor
    Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities.
    Inetetamab
  • HY-P99672
    Istiratumab
    		Inhibitor 98.45%
    Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers.
    Istiratumab
  • HY-150610
    EGFR-IN-69
    		Inhibitor 99.58%
    EGFR-IN-69 (compound 17g) is a potent EGFR inhibitor, with IC50 values of 4.3, 6.6 and 25.6 nM against EGFRL858R/T790M/C797S, EGFRL858R/T790M, and EGFR19del/T790M/C797S, respectively. EGFR-IN-69 can be used for non-small-cell-lung-cancer (NSCLC) research.
    EGFR-IN-69
  • HY-103439
    GW583340 dihydrochloride
    		Inhibitor
    GW 583340 dihydrochloride is a potent dual EGFR/ErbB2 tyrosine kinase inhibitor (IC50: 0.01 and 0.014 μM respectively). GW 583340 dihydrochloride reverses ABCG2- and ABCB1-mediated drug resistance. GW 583340 dihydrochloride has anti-cancer activity.
    GW583340 dihydrochloride
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
EGFR Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.